-
Product Insights
NewClinical Trials Scorecard for Investigations in 2023
This report provides an overview of global clinical trials with a start date between January 1, 2023, and December 31, 2023.
-
Innovation Ranking
NewInnovation Ranking – Ortho-Clinical Diagnostics Inc
Ortho Clinical Diagnostics Holdings Plc (OCD) designs, develops, manufactures, and markets diagnostic instruments, assays. It offers its products and solutions to hospitals, clinical laboratories, blood, and plasma centers across the world. The company’s products include clinical chemistry products used for measurement of target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; and Immunoassays for measurement of proteins, antibodies, and markers; donor screening and immunohematology products for blood and plasma screening. The company operates...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FRDA therapeutics. - More than 54,000 diagnosed prevalent cases of FRDA are anticipated in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FRDA. - The marketed drugs space for FRDA is limited to just two approved drugs, Biogen's Skyclarys (omaveloxolone) is the leading drug in FRDA space. - R&D efforts in the FRDA space are limited, with no pre-registration drugs currently in the...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in POP therapeutics. - In 2024, more than 34,000,000 incident cases of POP are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for POP. - Most marketed drugs for POP are enzyme inhibitors, followed by receptor agonists, by mechanism of action. - Phase III pipeline for POP is robust and includes 27 drugs, while pre-registration comprises four drugs. - Approximately 39.34% of the clinical trials...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
NewRetinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Report Overview Retinitis pigmentosa (RP) is a cluster of rare eye conditions. One of these conditions causes degeneration of the retina, the light-sensitive layer at the back of the eye. This degeneration results in a progressive loss of vision. Retinitis pigmentosa is an inherited genetic disorder. Most people have progressive vision loss over time, with symptoms usually starting in childhood. While there isn't a cure at this time, people can maximize their residual...
-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Epilepsy - Global Clinical Trials Review, 2024" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics. - More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PAD. - The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others. - The PAD pipeline mainly includes receptor agonists, followed by biological factor activators...